# Vor Biopharma Vor Biopharma is an Asset Manager based in Cambridge, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** Cambridge, United States - **Region:** North America - **Address:** Cambridge, MA, United States - **Founded:** 2015 - **Assets under management:** Undisclosed - **Website:** vorbio.com ## Regulatory record - **Reports private funds:** No ## About Vor Biopharma was founded in 2015 by a scientific team including Siddhartha Mukherjee, author of The Emperor of All Maladies, with early backing from PureTech Health and 5AM Ventures. The company is built around a technology platform licensed from Columbia University that engineers hematopoietic stem cells to lack specific proteins. By creating a transplant of gene-edited stem cells, Vor's approach allows patients to receive potent, targeted anti-cancer therapies that would otherwise destroy healthy blood cells alongside malignant ones. The firm went public via a standard IPO on the Nasdaq in February 2021. The company's pipeline centers on trembetelegene empogemeditemcel (trem-cel) for acute myeloid leukemia, with clinical-stage programs also investigating combinations with antibody-drug conjugates and CAR T therapies. Vor pursues a development-stage strategy across hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndromes. Its geographic focus is the United States, though its therapeutic approach addresses rare blood cancers globally. The firm has also published preclinical work on multiplexed-engineered stem cells resistant to multiple therapies simultaneously. Vor operates from Cambridge, Massachusetts, employing a team of research scientists, clinical developers, and cell-manufacturing specialists. In February 2024, Vor announced a strategic reorganization that included a workforce reduction and a pipeline refocus to prioritize its most advanced candidates. The company has no disclosed philanthropic arm or adjacent operating vehicles beyond its core drug-development engine. Vor's structural differentiator is its platform-and-pipeline model that combines a cell-therapy product with a companion therapeutic strategy. Unlike companies developing standalone cell therapies, Vor's "shielded" stem cells are designed specifically to be paired with antibody-based cancer drugs, making the drug the primary weapon and the engineered cell a biologic shield. This drug-plus-device architecture, where the transplant protects the patient rather than attacking the cancer directly, creates a regulatory and clinical development path distinct from single-modality oncology firms. ## Sectors - Biotech - Healthcare Services ## People - Robert Ang — President and Chief Executive Officer ## Questions ### Who runs investment decisions at Vor Biopharma? Vor Biopharma is an operating company, not an investment firm. Its President and CEO, Robert Ang, leads all corporate and strategic decisions. Ang joined as CEO in 2019 and previously served as Chief Business Officer at Neon Therapeutics. The board of directors, chaired by PureTech Health's Daphne Zohar, governs major financial allocations. ### What is Vor Biopharma's core technology? Vor develops gene-edited hematopoietic stem cells engineered to lack specific proteins targeted by cancer therapies. When transplanted into patients with blood cancer, these "shielded" cells survive anti-cancer drugs that kill unedited, cancerous cells. The lead program, tremtelectogene empogemeditemcel, targets CD33 in acute myeloid leukemia patients. This approach originated from research at Columbia University. ### Who founded Vor Biopharma, and what was the initial funding source? Vor Biopharma was founded in 2015, with Siddhartha Mukherjee, a Pulitzer Prize-winning author and oncologist, among the scientific founders. The company was incubated and initially financed by PureTech Health, a clinical-stage biotherapeutics company, alongside venture capital firm 5AM Ventures. A Series A round in 2016 raised further institutional backing. ### What investment stages does Vor Biopharma typically target? Vor does not invest in other companies. It is an oncology drug developer that allocates internal capital exclusively to its own research programs. All capital deployment is directed toward advancing its engineered-hematopoietic-stem-cell platform across preclinical and clinical trials, not toward managing a portfolio of external positions. ### Which sectors does Vor Biopharma explicitly focus on? Vor concentrates on hematologic malignancies, specifically acute myeloid leukemia and myelodysplastic syndromes. The company does not have disclosed programs outside blood cancers. Its technology platform is limited to modifying hematopoietic stem cells, which restricts its therapeutic scope to diseases addressable by bone marrow transplant. ### What is Vor Biopharma's known posture on co-investments alongside external GPs? Vor Biopharma does not participate in co-investments as an LP alongside general partners. As a publicly traded operating company, it is not structured as an institutional allocator. The firm raises its own capital through equity financings and spends it on internal research, without serving as a limited partner in third-party funds. ## Related profiles - [Arhaus](https://altss.com/profile/arhaus-inc) - [Riley Exploration Permian](https://altss.com/profile/riley-exploration-permian-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/vor-biopharma-inc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology